Merck Interest Income from 2010 to 2026

MRK Stock

USD 115.84 2.47 2.18%

Merck Interest Income yearly trend continues to be quite stable with very little volatility. Interest Income may rise above about 705 M this year. Interest Income is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. View All Fundamentals

Interest Income

First Reported

2019-03-31

Previous Quarter

61 M

Current Value

96 M

Quarterly Volatility

160.3 M

Covid

Interest Hikes

Check Merck financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Merck's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.8 B, Interest Expense of 1.5 B or Total Revenue of 77.5 B, as well as many indicators such as Price To Sales Ratio of 4.53, Dividend Yield of 0.0238 or PTB Ratio of 6.9. Merck financial statements analysis is a perfect complement when working with Merck Valuation or Volatility modules.

Build AI portfolio with Merck Stock

Check out the analysis of Merck Correlation against competitors.

Historical Interest Income data for Merck serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Merck Company represents a compelling investment opportunity.

Latest Merck's Interest Income Growth Pattern

Below is the plot of the Interest Income of Merck Company over the last few years. It is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. Merck's Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Merck's overall financial position and show how it may be relating to other accounts over time.

Interest Income

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Interest Income

Timeline

Merck Interest Income Regression Statistics

	Arithmetic Mean	735,661,176
	Geometric Mean	577,107,543
	Coefficient Of Variation	63.26
	Mean Deviation	381,730,657
	Median	704,990,000
	Standard Deviation	465,366,605
	Sample Variance	216566.1T
	Range	1.8B
	R-Value	(0.23)
	Mean Square Error	218853.2T
	R-Squared	0.05
	Significance	0.38
	Slope	(21,135,613)
	Total Sum of Squares	3465057.2T

Merck Interest Income History

	2026	705 M
	2025	477.2 M
	2024	415 M
	2023	390 M
	2022	1.3 B
	2021	1.9 B
	2020	59 M

Other Fundumenentals of Merck Company

Net Interest Income

Merck Interest Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Short Term Investments	Capital Stock	Common Stock	Long Term Debt	Good Will	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Total Permanent Equity	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Accumulated Depreciation	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital
Total Assets		0.88	0.64	0.91	0.93	0.91	0.98	0.22	0.59	0.5	-0.08	0.73	0.73	0.82	0.57	-0.47	0.56	0.35	-0.22	0.39	0.52	0.6	0.16	-0.03	-0.62	0.07	0.45	0.54	0.38
Total Stockholder Equity	0.88		0.23	0.66	0.73	0.62	0.9	0.03	0.78	0.12	0.17	0.6	0.6	0.51	0.23	-0.02	0.36	0.18	0.19	0.11	0.21	0.46	0.45	0.21	-0.43	-0.31	0.24	0.41	0.46
Net Debt	0.64	0.23		0.84	0.75	0.87	0.57	0.16	-0.1	0.84	-0.29	0.44	0.44	0.93	0.78	-0.9	0.62	0.58	-0.58	0.56	0.84	0.62	-0.45	-0.36	-0.52	0.46	0.52	0.58	0.19
Retained Earnings	0.91	0.66	0.84		0.95	0.96	0.9	0.17	0.27	0.71	-0.22	0.6	0.6	0.95	0.7	-0.73	0.68	0.57	-0.39	0.51	0.73	0.73	-0.14	-0.28	-0.58	0.26	0.67	0.68	0.45
Net Receivables	0.93	0.73	0.75	0.95		0.93	0.91	0.1	0.4	0.62	-0.31	0.58	0.58	0.91	0.63	-0.62	0.74	0.61	-0.27	0.51	0.69	0.76	0.01	-0.33	-0.55	0.12	0.59	0.7	0.48
Total Liab	0.91	0.62	0.87	0.96	0.93		0.87	0.31	0.31	0.75	-0.26	0.69	0.69	0.94	0.75	-0.76	0.63	0.45	-0.52	0.55	0.7	0.62	-0.13	-0.23	-0.67	0.37	0.55	0.55	0.26
Total Current Assets	0.98	0.9	0.57	0.9	0.91	0.87		0.2	0.56	0.44	-0.06	0.66	0.66	0.79	0.49	-0.41	0.57	0.37	-0.14	0.37	0.49	0.62	0.14	-0.05	-0.59	0.02	0.5	0.56	0.43
Short Term Debt	0.22	0.03	0.16	0.17	0.1	0.31	0.2		0.13	0.31	-0.3	0.45	0.45	0.07	0.24	-0.25	0.07	-0.33	-0.49	0.23	-0.04	-0.16	-0.06	0.04	-0.56	0.72	0.08	-0.19	-0.45
Intangible Assets	0.59	0.78	-0.1	0.27	0.4	0.31	0.56	0.13		0.0	0.15	0.65	0.65	0.1	0.14	0.19	0.15	-0.21	0.13	-0.05	-0.08	0.09	0.75	0.26	-0.42	-0.33	-0.1	0.04	0.13
Accounts Payable	0.5	0.12	0.84	0.71	0.62	0.75	0.44	0.31	0.0		-0.4	0.58	0.58	0.74	0.92	-0.91	0.7	0.42	-0.67	0.51	0.83	0.56	-0.42	-0.44	-0.61	0.53	0.65	0.56	0.24
Short Term Investments	-0.08	0.17	-0.29	-0.22	-0.31	-0.26	-0.06	-0.3	0.15	-0.4		0.11	0.11	-0.31	-0.22	0.42	-0.54	-0.51	0.36	-0.31	-0.36	-0.38	0.25	0.79	0.16	-0.46	-0.45	-0.36	-0.1
Capital Stock	0.73	0.6	0.44	0.6	0.58	0.69	0.66	0.45	0.65	0.58	0.11		1.0	0.47	0.74	-0.42	0.35	-0.2	-0.43	0.32	0.36	0.2	0.22	0.24	-0.71	0.19	0.22	0.18	0.1
Common Stock	0.73	0.6	0.44	0.6	0.58	0.69	0.66	0.45	0.65	0.58	0.11	1.0		0.47	0.74	-0.42	0.35	-0.2	-0.43	0.32	0.36	0.2	0.22	0.24	-0.71	0.19	0.22	0.18	0.1
Long Term Debt	0.82	0.51	0.93	0.95	0.91	0.94	0.79	0.07	0.1	0.74	-0.31	0.47	0.47		0.72	-0.79	0.72	0.69	-0.4	0.52	0.85	0.78	-0.31	-0.37	-0.49	0.27	0.65	0.74	0.43
Good Will	0.57	0.23	0.78	0.7	0.63	0.75	0.49	0.24	0.14	0.92	-0.22	0.74	0.74	0.72		-0.82	0.65	0.27	-0.65	0.52	0.82	0.52	-0.25	-0.23	-0.53	0.4	0.59	0.53	0.32
Treasury Stock	-0.47	-0.02	-0.9	-0.73	-0.62	-0.76	-0.41	-0.25	0.19	-0.91	0.42	-0.42	-0.42	-0.79	-0.82		-0.56	-0.49	0.74	-0.57	-0.76	-0.45	0.53	0.48	0.57	-0.6	-0.58	-0.44	-0.14
Property Plant Equipment	0.56	0.36	0.62	0.68	0.74	0.63	0.57	0.07	0.15	0.7	-0.54	0.35	0.35	0.72	0.65	-0.56		0.7	-0.17	0.4	0.86	0.87	-0.16	-0.63	-0.39	0.12	0.78	0.89	0.6
Current Deferred Revenue	0.35	0.18	0.58	0.57	0.61	0.45	0.37	-0.33	-0.21	0.42	-0.51	-0.2	-0.2	0.69	0.27	-0.49	0.7		0.06	0.32	0.7	0.83	-0.36	-0.69	-0.03	-0.02	0.64	0.83	0.62
Net Tangible Assets	-0.22	0.19	-0.58	-0.39	-0.27	-0.52	-0.14	-0.49	0.13	-0.67	0.36	-0.43	-0.43	-0.4	-0.65	0.74	-0.17	0.06		-0.51	-0.35	0.01	0.23	0.32	0.39	-0.83	-0.27	0.05	0.32
Total Permanent Equity	0.39	0.11	0.56	0.51	0.51	0.55	0.37	0.23	-0.05	0.51	-0.31	0.32	0.32	0.52	0.52	-0.57	0.4	0.32	-0.51		0.44	0.34	-0.02	-0.38	-0.33	0.34	0.39	0.31	0.12
Long Term Debt Total	0.52	0.21	0.84	0.73	0.69	0.7	0.49	-0.04	-0.08	0.83	-0.36	0.36	0.36	0.85	0.82	-0.76	0.86	0.7	-0.35	0.44		0.83	-0.42	-0.49	-0.32	0.22	0.74	0.85	0.55
Capital Surpluse	0.6	0.46	0.62	0.73	0.76	0.62	0.62	-0.16	0.09	0.56	-0.38	0.2	0.2	0.78	0.52	-0.45	0.87	0.83	0.01	0.34	0.83		-0.19	-0.51	-0.14	-0.03	0.78	0.97	0.75
Deferred Long Term Liab	0.16	0.45	-0.45	-0.14	0.01	-0.13	0.14	-0.06	0.75	-0.42	0.25	0.22	0.22	-0.31	-0.25	0.53	-0.16	-0.36	0.23	-0.02	-0.42	-0.19		0.19	0.06	-0.38	-0.32	-0.22	-0.06
Long Term Investments	-0.03	0.21	-0.36	-0.28	-0.33	-0.23	-0.05	0.04	0.26	-0.44	0.79	0.24	0.24	-0.37	-0.23	0.48	-0.63	-0.69	0.32	-0.38	-0.49	-0.51	0.19		0.05	-0.31	-0.57	-0.5	-0.21
Accumulated Depreciation	-0.62	-0.43	-0.52	-0.58	-0.55	-0.67	-0.59	-0.56	-0.42	-0.61	0.16	-0.71	-0.71	-0.49	-0.53	0.57	-0.39	-0.03	0.39	-0.33	-0.32	-0.14	0.06	0.05		-0.29	-0.19	-0.14	0.08
Short Long Term Debt	0.07	-0.31	0.46	0.26	0.12	0.37	0.02	0.72	-0.33	0.53	-0.46	0.19	0.19	0.27	0.4	-0.6	0.12	-0.02	-0.83	0.34	0.22	-0.03	-0.38	-0.31	-0.29		0.28	-0.06	-0.41
Cash And Equivalents	0.45	0.24	0.52	0.67	0.59	0.55	0.5	0.08	-0.1	0.65	-0.45	0.22	0.22	0.65	0.59	-0.58	0.78	0.64	-0.27	0.39	0.74	0.78	-0.32	-0.57	-0.19	0.28		0.81	0.7
Net Invested Capital	0.54	0.41	0.58	0.68	0.7	0.55	0.56	-0.19	0.04	0.56	-0.36	0.18	0.18	0.74	0.53	-0.44	0.89	0.83	0.05	0.31	0.85	0.97	-0.22	-0.5	-0.14	-0.06	0.81		0.81
Net Working Capital	0.38	0.46	0.19	0.45	0.48	0.26	0.43	-0.45	0.13	0.24	-0.1	0.1	0.1	0.43	0.32	-0.14	0.6	0.62	0.32	0.12	0.55	0.75	-0.06	-0.21	0.08	-0.41	0.7	0.81

Click cells to compare fundamentals

About Merck Financial Statements

Merck investors utilize fundamental indicators, such as Interest Income, to predict how Merck Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Interest Income	477.2 M	705 M
Net Interest Income	-770.4 M	-808.9 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet

When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:

How To Invest In Merck

Details

Is Merck Stock a good investment?

Details

What is Merck's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Merck Correlation against competitors.

You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. Expected growth trajectory for Merck significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Merck assessment requires weighing all these inputs, though not all factors influence outcomes equally.

Quarterly Earnings Growth

0.87

Dividend Share

3.2

Earnings Share

7.56

Revenue Per Share

25.559

Quarterly Revenue Growth

0.037

Understanding Merck Company requires distinguishing between market price and book value, where the latter reflects Merck's accounting equity. The concept of intrinsic value - what Merck's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Merck's price substantially above or below its fundamental value.

Understanding that Merck's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Merck represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Merck's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Merck Interest Income from 2010 to 2026

Latest Merck's Interest Income Growth Pattern

Merck Interest Income Regression Statistics

Merck Interest Income History

Other Fundumenentals of Merck Company

Merck Interest Income component correlations

About Merck Financial Statements

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY